Lymphokines Or Monokines Patents (Class 435/69.5)
  • Patent number: 10561712
    Abstract: The beta 2 subunit of mouse hemoglobin (HBB2) has been identified as soluble factor from mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung micrometastases. The beta subunit of human hemoglobin (HBB) has been found to have similar activity. Methods of using these proteins and fragments thereof in the treatment of cancer and inhibition of metastasis are provided, along with methods of screening a subject for micrometastases by detecting HBB in a biological sample.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: February 18, 2020
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Wuyuan Lu, Issac Witz, Shelly Maman
  • Patent number: 10456425
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: October 29, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Patent number: 10370433
    Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Biontech AG
    Inventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
  • Patent number: 10227415
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 12, 2019
    Assignee: ZYMOGENETICS INC.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Patent number: 10196662
    Abstract: This invention generally relates to a composition and its production method useful for developing drugs and/or therapies for enhancing wound healing, in particular scarless wound healing. Particularly, the present invention teaches the essential processes necessary for producing and purifying embryonic stem cell (ESC)-specific RNA compositions, such as messenger RNAs (mRNA), microRNA precursors (pre-miRNA), and small hairpin RNAs (shRNA), which are useful for treating human diseases and lesions.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 5, 2019
    Assignee: MELLO BIOTECHNOLOGY, INC.
    Inventors: David T S Wu, Shi-Lung Lin, Jack S. K. Chen
  • Patent number: 9840543
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith Canada, Mlchael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John James Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Patent number: 9821011
    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 21, 2017
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Charles L. Sentman
  • Patent number: 9822180
    Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: November 21, 2017
    Assignee: THE UNIVERSITY OF BIRMINGHAM
    Inventors: Mark Cobbold, David Millar
  • Patent number: 9783811
    Abstract: Eukaryotic protein-coding messenger RNAs and non-coding microRNAs are naturally transcribed by type II RNA polymerases (pol-2) but not prokaryotic RNA polymerases. As a result, current eukaryotic RNA and protein production is performed either using eukaryotic pol-2 promoters in hybridomas or mammalian cells or using prokaryotic promoters in bacterial cells. However, because prokaryotic RNA transcription tends to be error-prone, frequent mutation is a big problem. Also, growing hybridomas or mammalian cells is relatively laborious and costly. To overcome these problems, the present invention provides a novel inducible composition and method for producing eukaryotic RNAs and/or their related peptides/proteins directly using eukaryotic pol-2 promoter-driven gene expression in fast growing bacteria, without the need of changing to prokaryotic promoters or growing hybridomas/mammalian cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: October 10, 2017
    Assignee: MELLO BIOTECHNOLOGY, INC.
    Inventors: Shi-Lung Lin, Donald C. Chang
  • Patent number: 9738700
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: August 22, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Patent number: 9657076
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: May 23, 2017
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Patent number: 9637747
    Abstract: Eukaryotic protein-coding messenger RNAs and non-coding microRNAs are naturally transcribed by type II RNA polymerases (pol-2) but not prokaryotic RNA polymerases. As a result, current eukaryotic RNA and protein production is performed either using eukaryotic pol-2 promoters in hybridomas or mammalian cells or using prokaryotic promoters in bacterial cells. However, because prokaryotic RNA transcription tends to be error-prone, frequent mutation is a big problem. Also, growing hybridomas or mammalian cells is relatively laborious and costly. To overcome these problems, the present invention provides a novel inducible composition and method for producing eukaryotic RNAs and/or their related peptides/proteins directly using eukaryotic pol-2 promoter-driven gene expression in fast growing bacteria, without the need of changing to prokaryotic promoters or growing hybridomas/mammalian cells.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: May 2, 2017
    Assignee: MELLO BIOTECHNOLOGY, INC.
    Inventors: Shi-Lung Lin, Donald C. Chang
  • Patent number: 9624276
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: April 18, 2017
    Assignee: The California Institute for Biomedical Research
    Inventors: Travis Young, Chanhyuk Kim, Peter G. Schultz
  • Patent number: 9534037
    Abstract: Embodiments disclosed herein provide systems and methods that increase protein yield from recombinant manufacturing processes. The systems and methods treat used depth filters with bound proteins of interest as a stationary phase exchange resin to recapture bound protein of interest from the depth filter.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: January 3, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Sylvain Roy, Ganesh Vissvesvaran
  • Patent number: 9469681
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 18, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Patent number: 9255152
    Abstract: The present invention relates to a novel epitope to convert T cell to type 2 helper T (TH2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 9, 2016
    Assignee: National Cancer Center
    Inventor: Byoung Se Kwon
  • Patent number: 9212213
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: December 15, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Patent number: 9200049
    Abstract: The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: December 1, 2015
    Assignee: Novo Nordisk A/S
    Inventor: Shawn DeFrees
  • Patent number: 9095552
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 4, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Tirtha Chakraborty, Antonin de Fougerolles
  • Patent number: 9079976
    Abstract: The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: July 14, 2015
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Haval Shirwan, Kutlu G. Elpek, Esma S. Yolcu
  • Patent number: 9056081
    Abstract: The invention relates to a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for treating or preventing a Pseudomonas infection, in particular an infection with Pseudomonas aeruginosa. The invention further relates to the use of a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for the preparation of a pharmaceutical composition for treating or preventing a Pseudomonas infection. The invention also relates to a pharmaceutical composition comprising a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide, wherein the composition is for treating or preventing a Pseudomonas infection.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: June 16, 2015
    Assignees: Universitätsklinikum Hamburg-Eppendorf, Heinrich-Heine-Universität Düsseldorf
    Inventors: Melita Schachner, Heike Gustke, Udo Schumacher, Karl-Erich Jäger
  • Patent number: 8993519
    Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: March 31, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Jason Benjamin Bock, Xia Luo
  • Publication number: 20150072368
    Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.
    Type: Application
    Filed: February 8, 2013
    Publication date: March 12, 2015
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, François Coutard
  • Publication number: 20150064236
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: March 9, 2013
    Publication date: March 5, 2015
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Publication number: 20150044720
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Application
    Filed: October 3, 2014
    Publication date: February 12, 2015
    Applicant: Octapharma AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Patent number: 8945872
    Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David S. Scher, Roger E. Harrington
  • Patent number: 8937169
    Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: January 20, 2015
    Assignee: Human Genome Sciences, Inc.
    Inventor: Yi Li
  • Publication number: 20150017685
    Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 15, 2015
    Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
  • Patent number: 8906649
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 9, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
  • Publication number: 20140356326
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 4, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
  • Publication number: 20140298508
    Abstract: The present invention is directed to alpha-mannosidase sequences from plants and the use thereof, especially genomic nucleotide sequences containing the regulatory elements controlling their expression, intron and exon sequences and polynucleotide sequences coding for alpha-mannosidase enzymes. Such plants with modified alpha-mannosidase activity can be used for the production of glycoproteins having an altered saccharide composition of great benefit. The present invention also relates to the use of these alpha-mannosidase enzymes for hydrolyzing mannoses.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 2, 2014
    Applicant: PHILIP MORRIS PRODUCTS S.A.
    Inventors: Nikolai Valeryevitch Ivanov, Prisca Camponini, Dionisius Florack, Karen Oishi
  • Publication number: 20140255345
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 11, 2014
    Applicant: Allozyne, Inc.
    Inventors: Kenneth H. Grabstein, David A. Tirrell
  • Publication number: 20140220631
    Abstract: Disclosed are a method for rapid screening of suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 7, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jung-Hoon SOHN, Eui-Sung CHOI, Jung-Hoon BAE, Eung-Suck LEE, Mi-Kyung SHIN
  • Publication number: 20140193357
    Abstract: The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo.
    Type: Application
    Filed: August 9, 2011
    Publication date: July 10, 2014
    Inventors: Edita Mistiniene, Jonas Henrikas Pesliakas, Milda Pleckaityte, Gintautas Zvirblis
  • Patent number: 8771664
    Abstract: The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: July 8, 2014
    Assignees: Fundacion para la Investigacion Medica Aplicada, Research Center Borstel
    Inventors: Pedro Berraondo Lopez, Jessica Fioravanti, Jose Medina Echeverz, Ignacio Javier Melero Bermejo, Maria del Carmen Ochoa Nieto, Francisco de Asis Palazon Garcia, Silvia Bulfone-Paus, Erwin Hans Duitmann
  • Publication number: 20140178329
    Abstract: Described are novel variants of APRIL that modulate signaling via receptor-specific agonist activity, and nucleic acids encoding these variant proteins. Further described is the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders.
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Applicants: Institucio Catalana de Recerca I Estudis Avancats (ICREA), Fundacio Privada Centre de Regulacio Genomica (CRG)
    Inventors: Luis Serrano Pubul, Albert Martinus Van Der Sloot, Jan Paul Medema, Fiona Clare Kimberley
  • Publication number: 20140154213
    Abstract: The present invention relates to a recombinant vector for expressing and secreting, by a propionibacterium, at least one eukaryotic peptide or protein of interest, comprising at least: under the control of at least one suitable promoter, at least one nucleic acid sequence encoding a propionibacterial signal peptide and, at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest; wherein said at least one nucleic acid sequence encoding a propionibacterial signal peptide is translationally fused to said at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest. The invention further relates to the uses of such a vector in the pharmaceutical field or for the large-scale production of peptides or proteins of interest.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 5, 2014
    Applicants: UNIVERSITE DE RENNES 1, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Gwenael JAN, Marie-Thérése DIMANCHE-BOITREL, Héléne FALENTIN, Charles HALOUZE
  • Publication number: 20140058790
    Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.
    Type: Application
    Filed: November 30, 2011
    Publication date: February 27, 2014
    Applicant: AmideBio LLC
    Inventors: Michael H.B. Stowell, Mikhail Plam
  • Publication number: 20130324593
    Abstract: The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a ?-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a ?-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine.
    Type: Application
    Filed: November 29, 2011
    Publication date: December 5, 2013
    Applicant: LG Life Sciences Ltd
    Inventors: Yeon Chul Kim, Saem Jung, Jun Jung
  • Patent number: 8598318
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 3, 2013
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Publication number: 20130244280
    Abstract: The present invention provides an expression vector for the production of proteins and peptides comprising a promoter operably linked to gene of interest, TPL and VA genes I and II, matrix attachment regions (MARs)/SARs, and antibiotic marker. The vector is transfected in suitable host cell.
    Type: Application
    Filed: October 10, 2011
    Publication date: September 19, 2013
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Aashini Parikh, Arun Singh, Sanjeev Kumar Mendiratta, Ajit K Gupta, Mansi Jakhade
  • Patent number: 8492120
    Abstract: The present invention discloses an improved process for the production of G-CSF in high yield via a high salt-induced increase in plasmid stability during the production phase.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: July 23, 2013
    Assignee: Cadila Healthcare Limited
    Inventors: Sanjeev Kumar Mendiratta, Vibhor Saraswat, Pankaj R. Patel
  • Publication number: 20130164251
    Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.
    Type: Application
    Filed: June 30, 2010
    Publication date: June 27, 2013
    Inventors: Xiaofang Wen, Yiliang Wu, Yefei Wang, Zhiyu Yang, Min Fan, Yujiao Wang, Xiaochun Fang, You Lu
  • Patent number: 8455218
    Abstract: The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to expression of soluble, active recombinant protein by using secretion signals to direct the protein to the periplasmic space of a bacterial cell. In particular, the present invention relates to a production process for obtaining soluble hG-CSF protein from a bacterial host.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: June 4, 2013
    Assignee: Pfenex, Inc.
    Inventors: Hongfan Jin, Lawrence Chew
  • Publication number: 20130122546
    Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.
    Type: Application
    Filed: March 17, 2011
    Publication date: May 16, 2013
    Applicant: LFB BIOTECHNOLOGIES
    Inventor: Alexandre Fontayne
  • Publication number: 20130108578
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: May 2, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • Publication number: 20130101549
    Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.
    Type: Application
    Filed: October 25, 2012
    Publication date: April 25, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • Patent number: 8426573
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: April 23, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
  • Patent number: 8420100
    Abstract: Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: April 16, 2013
    Assignees: Department of Biotechnology, National Centre for Cell Science
    Inventors: Samit Chattopadhyay, Archana Jalota-Badhwar